Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marta Mongillo
Observed name:
M. Mongillo
Institution:
European Institute of Oncology
Observed institutions:
University of Verona,
Azienda Ospedaliera Universitaria Integrata Verona,
Ospedale San Bortolo,
Istituti di Ricovero e Cura a Carattere Scientifico,
European Institute of Oncology
ORCID:
0009-0004-4960-7759
Observed ORCID:
0009-0004-4960-7759
OpenAlex ID:
A5069132302
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
2020
·
Serena Zuliani
, Ilaria Zampiva
, et al.
·
European Journal of Cancer
·
32
PDF
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
2022
·
Marzia Del Re
, Stefania Crucitta
, et al.
·
The Breast
·
23
PDF
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
2024
·
C. Valenza
, M. Mongillo
, et al.
·
ESMO Open
·
7
PDF
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
2025
·
Carmine Valenza
, Marta Mongillo
, et al.
·
Gynecologic Oncology
·
6
Comparing immunotherapies to other frequently used treatments of gastric cancer
2021
·
Debora Basile
, Francesca Simionato
, et al.
·
Expert Review of Clinical Pharmacology
·
3
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
2026
·
Lucy Haggstrom
, Yeh Chen Lee
, et al.
·
JAMA Oncology
·
2
PDF
Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201
2026
·
Rachel Grisham
, Els Van Nieuwenhuysen
, et al.
·
Gynecologic Oncology
·
2
1701P Oncological patients’ perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic
2020
·
D. Tregnago
, S. Zuliani
, et al.
·
Annals of Oncology
·
2
PDF
Impact of neoadjuvant chemotherapy on homologous recombination deficiency test results in patients with advanced high-grade serous ovarian cancer
2026
·
Ilaria Betella
, Diletta Fumagalli
, et al.
·
International Journal of Gynecological Cancer
·
1
Impact of treatment-emergent ocular events on health-related quality of life in patients with folate receptor alpha-positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine: Results from the phase III MIRASOL study
2025
·
Tashanna Myers
, Kathleen Moore
, et al.
·
Gynecologic Oncology
·
1
1077P How long is long enough? An international GCIG collaboration investigating long term outcomes of exceptional responders with platinum sensitive recurrent ovarian cancer treated with PARP inhibitors
2025
·
L. Haggstrom
, Y.C. Lee
, et al.
·
Annals of Oncology
·
1
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2024
·
Carmine Valenza
, Eleonora Nicolò
, et al.
·
The Oncologist
·
1
2148P Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
2023
·
L. Gervaso
, C. Valenza
, et al.
·
Annals of Oncology
·
1
Evolution of treatment strategies for advanced epithelial ovarian cancer: a 16-year overview from a referral center
2026
·
Lucia Ribero
, Diletta Fumagalli
, et al.
·
International Journal of Gynecological Cancer
Molecular Profiling and Tumor Biomarker Analysis of Ramp 201, a Study Demonstrating Efficacy of Avutometinib in Combination With Defactinib in Recurrent Low-grade Serous Ovarian Cancer
2026
·
Susana Banerjee
, Carol Aghajanian
, et al.
·
International Journal of Gynecological Cancer
1088P Metastasis-directed stereotactic radiotherapy (mdSBRT) for patients (pts) with oligoprogressive, oligorecurrent or oligopersistent (oligo-pr/re/pe) high grade ovarian cancer (HGOC)
2025
·
M. Mongillo
, J. Katrini
, et al.
·
Annals of Oncology
92P Metastasis-directed stereotactic radiotherapy (mdSBRT) for patients (pts) with oligoprogressive, oligorecurrent or oligopersistent (oligo-pr/r/pe) less common ovarian cancers (lcOCs)
2025
·
J. Katrini
, M. Mongillo
, et al.
·
ESMO Open
PDF
Association Of KELIM Score And Böhm’s Chemotherapy Response Score With Disease-Free Survival In Patients With Advanced Ovarian Cancer
2025
·
Marina Rosanu
, Luigi A. De Vitis
, et al.
·
International Journal of Gynecological Cancer
Trends In The Surgical Treatment Of Advanced Epithelial Ovarian Cancer: A 10-Year Perspective From A Referral Center
2025
·
Lucia Ribero
, Gabriella Schivardi
, et al.
·
International Journal of Gynecological Cancer
PT004/#583 Successful carboplatin desensitization protocol in patients with proven or increased risk of carboplatin hypersensitivity reaction
2024
·
Mariateresa Lapresa
, Giuseppe Caruso
, et al.
·
International Journal of Gynecological Cancer
PDF
2041P The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
2023
·
C. Valenza
, E. Nicolo
, et al.
·
Annals of Oncology
PDF
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience
2022
·
A. Caldart
, E. Fiorio
, et al.
·
European Journal of Cancer
1683P Implementing next generation sequencing (NGS)/molecular tumor board (MTB)-based precision oncology practice: One-year experience at the Verona University Hospital
2022
·
S.T. Riva
, C. Luchini
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
23
Citation count:
82
H-index:
4
I10-index:
2
Year
Topic
Type